Baylor Researchers Identified VAV1-Degrading Compounds

The study offers a potential new strategy to target proteins implicated in blood cancers and autoimmune diseases.

Updated on Sept. 30, 2026 in Biotech

Bold flat-color editorial illustration showing an abstract protein structure and binding molecule, representing targeted medical research. — Baylor College of Medicine researchers identified molecular glue compounds capable of degrading the VAV1 protein, a potential therapeutic breakthrough for blood cancers. AI Illustration. Upload story photo >

Live Poll

Do you believe the use of artificial intelligence to develop new medical treatments is beneficial?

Researchers at Baylor College of Medicine have identified molecular glue compounds that degrade the VAV1 protein in human T cells. Published in Nature Communications on September 30, 2026, this research remains in the discovery phase.

Why it matters

VAV1 is a key protein implicated in blood cancers and autoimmune disorders, making it a high-value target for therapeutic intervention. This research introduces a mechanism to eliminate the protein rather than merely inhibiting its activity.

The study identified the compound NGT-201-12 through high-throughput proteomics, while NGT-201-18 demonstrated potent degradation of VAV1 and the secondary protein LIMD1. Both compounds require the proteasome—the cellular machinery for protein recycling—and the cereblon protein to function.

The players

Baylor College of Medicine

A Houston-based medical institution focused on biomedical research and health sciences, home to the laboratory that led the VAV1 study.

Jin Wang

A lead researcher at Baylor College of Medicine specializing in the development of chemical probes and therapeutic protein degradation.

Hanfeng Lin

A lead researcher at Baylor College of Medicine focused on proteomics and the discovery of novel chemical mechanisms for protein regulation.

The details

The team utilized GluePlex, a system that integrates AI-based protein-structure prediction with physics-based modeling to simulate the assembly of a ternary complex, which is a molecule that bridges two proteins together. By identifying molecular glues—small molecules that induce the degradation of specific disease-causing proteins—researchers can effectively mark target proteins like VAV1 for destruction by the cell. These studies are currently limited to cell-based findings and require further validation in vivo.

September 30, 2026: The study was published in Nature Communications.

The Tech Race

This work advances the competitive field of targeted protein degradation, which aims to move beyond traditional small-molecule inhibitors that often fail to fully silence protein activity. By deploying GluePlex, the team aims to accelerate the discovery of compounds that bridge proteins for destruction within the crowded landscape of proteomic research.

This research provides a new experimental tool for Houston-based labs and oncologists studying aggressive blood cancers. The discovery remains at the bench-science stage, and the compounds are not yet available for clinical testing or therapeutic use in patients.

The takeaway

The study demonstrates that VAV1 can be successfully targeted for degradation in human T cells, offering a new pathway for potential drug development. Future progress depends on subsequent studies assessing whether these compounds can maintain selectivity and safety in more complex disease models.